Business Wire

Maltese Falcon Successfully Completes First-Ever Sailing Yacht Trials with Kymeta and e3 Systems

Del

Redmond, Washington-based Kymeta, Intelsat S.A. (NYSE: I)—operator of the world’s first Globalized Network—and exclusive superyacht distribution partner e3 Systems today revealed that the Maltese Falcon, the iconic 89-meter sailing vessel, has been performing the first-ever sailing yacht sea trials with Kymeta communications solutions over the past four months with successful results. The Maltese Falcon, with its trial installation of Kymeta KyWay terminals, will be at the Monaco Yacht Show.

Kymeta and e3 worked with the executive management, the Captain, and the IT manager of the Maltese Falcon to perform the months-long sea trials, which commenced in the Caribbean and are ongoing. During the trials the yacht was equipped with both single and multiple-terminal configurations. Upon commercial release of yacht solutions, the terminals will be bundled with Kymeta’s KĀLO™ internet access services, powered by the IntelsatOne® Flex for Maritime service. The trial utilized capacity on three Intelsat assets, IS-29e (Caribbean), IS-32e Wide Beam (Bermuda/Atlantic), and IS-905 (Europe).

The trial experience has proven valuable for the captain and crew of the Maltese Falcon. Captain Nikolaos Leontitsis of the Maltese Falcon said, “We were thrilled to partner with Kymeta on this sea trial because connectivity is critical on the water. Kymeta's consistent connection allows us to maximize the use of the Falcon's sophisticated onboard network, and to offer our guests and crew cutting edge communications and internet service together with the latest in on-demand entertainment options.”

The crew of the Maltese Falcon worked with Kymeta and e3 to adapt the installed KyWay panel throughout the trial period.

“We recently installed additional Kymeta KyWay terminals on the Maltese Falcon to enable truly global connectivity,” said Roger Horner, Managing Director at e3. “The yacht adapted very successfully from using a single KyWay terminal during the initial sea trials by moving it to avoid mast shadow. It now has four terminals for the full-scale temporary installation which addresses the mast shadow challenges while awaiting embedded installation.”

The experience, and the weather, provided the engineering teams at Kymeta and e3 with valuable insights for maritime installations before the product becomes commercially available. “We observed that the panel remained connected regardless of sea motion, pitch and roll, and exceeded our initial expectations of the performance of the electronically-steered beam,” said Håkan Olsson, Vice President of Maritime at Kymeta. “The yacht industry can now look forward to not only the possibility, but the reality, of domeless vessels and communication capabilities we never would have thought possible even a decade ago.”

Captain Leontitsis recognized additional benefits for the future and is looking forward to further technology solutions as a result of installing Kymeta’s panels on the Maltese Falcon. “The sea trials with Kymeta aboard the Maltese Falcon offered an altogether different communications experience,” said Captain Leontitsis. “It is very exciting to work with our innovative executive management team, which selects and is able to apply the most appropriate and advanced technology on the Maltese Falcon.”

About SY Maltese Falcon

The Maltese Falcon is not a classic yacht, she's a new class of yacht. Her revolutionary sailing system—the Falcon Rig—sets a new milestone in yachting history: 3 self-standing and rotating masts hosting 15 sails for a total sail area of 2,400 square meters (25,791 ft square), handled by the ultimate in Perini Navi Sail Control for unrivaled performance with unmatched safety and maneuverability characteristics. The iconic Maltese Falcon was built for the late Tom Perkins from whom it was purchased by Pleon Ltd, for the purpose of creating a unique chartering experience. For more information, visit symaltesefalcon.com.

About Kymeta

What’s the missing link to connecting billions of people to high-speed mobile access? Antennas. And Kymeta offers the world’s only commercially-viable electronically-scanning satellite antennas and terminals. Kymeta antennas and terminals deliver high-throughput communications for land, sea, and air, making mobile connectivity as available as a view of the sky. Plus, the world’s largest satellite operator, Intelsat, has joined forces with Kymeta to deliver KĀLO global access services that combine with Kymeta antennas and terminals to provide revolutionary mobile connectivity. Without Kymeta mTenna™ technology, connecting and staying connected to all those new satellites while on the move will be difficult, if not impossible.

If it moves, Kymeta will keep it connected. Anywhere.

For more information, visit kymetacorp.com and KALO.net.

About e3 Systems

e3 Systems® is a leading communications integrator and solutions provider for the marine industry. The company connects yachts globally through a diverse portfolio of communication systems including its HYBRID solution which synchronises VSAT, Inmarsat, Iridium, 3G, 4G and Wi-Fi. In addition, e3 provides an extensive suite of services covering cyber security and training, IT support, data management and content provision. e3 operates from the Mediterranean and the USA with partners worldwide. It is part of the marine electronics group grupoarbulu.

Discover more at e3s.com.

About Intelsat

Intelsat S.A. (NYSE: I) operates the world’s first Globalized Network, delivering high-quality, cost-effective video and broadband services anywhere in the world. Intelsat’s Globalized Network combines the world’s largest satellite backbone with terrestrial infrastructure, managed services and an open, interoperable architecture to enable customers to drive revenue and reach through a new generation of network services. Thousands of organizations serving billions of people worldwide rely on Intelsat to provide ubiquitous broadband connectivity, multi-format video broadcasting, secure satellite communications and seamless mobility services. The end result is an entirely new world, one that allows us to envision the impossible, connect without boundaries and transform the ways in which we live. For more information, visit www.intelsat.com and www.intelsat.com/intelsatone-flex/maritime.

Contact information

Business Inquiries for Kymeta:
Kymeta Corporation
Lisa Dreher, +1-425-658-8724
Director of Marketing
ldreher@kymetacorp.com
or
Media Inquiries for Kymeta:
The Summit Group
Amy Oliver, +1-801-990-1185
PR/Content Manager
aoliver@summitslc.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third